XOMA 358

Drug Profile

XOMA 358

Alternative Names: X 358; XOMA 247; XOMA358; XPA.15.247

Latest Information Update: 26 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator XOMA
  • Class Antihyperglycaemics; Monoclonal antibodies
  • Mechanism of Action Insulin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperinsulinaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperinsulinaemia; Hypoglycaemia

Most Recent Events

  • 26 Apr 2017 Xoma plans a phase IIb trial for Congenital hyperinsulinism (children) in United Kingdom in the second half of 2017
  • 01 Apr 2017 Updated efficacy data from a phase II trial in Hyperinsulinaemia presented at the 99th Annual Meeting of the Endocrine Society (ENDO-2017)
  • 20 Jan 2017 XOMA completes a phase II trial in Hyperinsulinaemia (In adolescents, In adults) in Germany (IV) (EudraCT2016-001275-80)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top